About Vanda Pharmaceuticals
Vanda Pharmaceuticals (NASDAQ:VNDA) is a biopharmaceutical company focused on the development and commercialization of innovative therapies to address unmet medical needs. The company’s portfolio includes products in the areas of psychiatry, neurology, and dermatology, among others. Vanda is committed to improving patient outcomes through research and development of novel treatments. Key projects include treatments for conditions such as schizophrenia, non-24-hour sleep-wake disorder, and atopic dermatitis. Vanda’s objectives consist of advancing its clinical development programs, expanding its product portfolio through strategic partnerships and acquisitions, and delivering sustainable growth. The company strives to make a meaningful difference in patients' lives through its pioneering work in the healthcare sector.
Snapshot
Operations
Products and/or services of Vanda Pharmaceuticals
- HETLIOZ (tasimelteon) - Treatment for Non-24-Hour Sleep-Wake Disorder (Non-24) and Smith-Magenis Syndrome-related sleep disorders.
- Fanapt (iloperidone) - An antipsychotic medication for the treatment of schizophrenia.
- Tradipitant - An investigational new drug potentially for the treatment of gastroparesis, atopic dermatitis, and motion sickness.
- VLY-686 (Tradipitant) - A neurokinin-1 receptor antagonist, in development stages for various conditions including chronic pruritus and cough.
- HETLIOZ LQ - A liquid formulation of tasimelteon designed for individuals who have difficulty swallowing capsules, targeting Non-24-Hour Sleep-Wake Disorder.
Vanda Pharmaceuticals executive team
- Dr. Mihael H. Polymeropoulos M.D.Founder, President, CEO & Chairman of The Board
- Mr. Kevin Patrick MoranSenior VP, CFO & Treasurer
- Mr. Timothy Williams J.D.Senior VP, General Counsel & Secretary
- Mr. Joakim WijkstromSenior VP & Chief Marketing Officer
- Mr. Gunther BirznieksSenior Vice President of Business Development
- Mr. Scott L. HowellChief People Officer